Healthcare
LHI Technology is a manufacturer of medical cables with offices in China, Singapore, the US, and Germany. The company’s complex products are used in challenging environments to provide real time information for patients; only a handful of players globally have this capability
During our ownership, the company evolved from a business focused predominantly on blood oxygen monitoring into one offering more technically demanding and higher performance products, including ECG and ultrasound cables and cables for surgical and video endoscopy applications, including ultrasound.
Working with management, we implemented several operational improvements, including increasing the company’s technical capabilities and optimising key costs.
“3i’s comprehensive knowledge and network in the healthcare industry gave LHi an increased scope and expansion possibilities that we never had before." Jay Pok, Founder, LHi Technology
Regulatory information
This transaction involved a recommendation of 3i Investments plc, advised by 3i Singapore.
Healthcare
Quintiles delivered transformational growth to become the world’s largest provider of life sciences product development and integrated healthcare services. It helps biopharmaceutical customers, as well as other healthcare customers, navigate the increasingly complex healthcare environment to improve efficiency and deliver better healthcare outcomes.
During our ownership, Quintiles expanded its commercial services into the Middle East, North Africa and East Africa, and developed numerous clinical development and joint venture partnerships. The business also expanded its Real-World & Late Phase offering through acquisitions and strategic partnerships. Quintiles has an extensive reach and has helped develop or commercialise most of the top biopharmaceutical and biologic products on the market today.
In November 2017, post 3i’s exit, Quintiles adopted the name of IQVIA
“We are proud to have supported the business and its management team during this period of transformational growth and would like to thank them for their partnership over the years.” Richard Relyea, Partner, 3i North America
Regulatory information
This transaction involved a recommendation of 3i Corporation, a US wholly owned subsidiary of 3i Group. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this release. For data relating to other assets involving a past recommendation by 3i Corporation please click here.
Healthcare
Founded in 2000, Vedici is one of the main providers of private acute care in France. Upon 3i’s exit, it was the fourth largest provider, had c.6,000 staff and ran c.4500 beds in 35 care facilities located between Paris and southern / south-western France.
3i invested in Vedici in 2010 to support both its organic and buy-and-build growth strategies.
“3i’s extensive support has helped us strengthen the leadership team, increase scale quickly and improve operational efficiency. Today, we look forward to continuing to build on our success in order to become the partner of choice to all local authorities in France.” Jérôme Nouzarède, CEO, Vedici
Regulatory information
This transaction involved a recommendation of 3i Investments plc, advised by 3i France.
Healthcare
Xellia is a specialty pharmaceutical group focused on the development, manufacturing and global commercialisation of anti-infective therapies. During our ownership, Xellia transformed from a supplier of niche active pharmaceutical ingredients to a fully integrated speciality pharmaceutical company.
During our investment period, Xellia invested more than $100 million in research and development (‘R&D’) and capacity expansion across its global manufacturing network, including a new fill-finish plant in Copenhagen.
“3i’s investment and continued support, expertise and commitment has enabled Xellia to successfully grow and transition the business to become leaders in the supply of key anti-infective products.” Carl-Åke Carlsson, Chief Executive and President, Xellia
Regulatory information
This transaction involved a recommendation of 3i Investments plc, advised by 3i Sweden.